Zacks: Analysts Expect Genomic Health, Inc. (GHDX) Will Announce Quarterly Sales of $89.13 Million

Wall Street brokerages predict that Genomic Health, Inc. (NASDAQ:GHDX) will post $89.13 million in sales for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Genomic Health’s earnings, with estimates ranging from $88.70 million to $90.06 million. Genomic Health reported sales of $82.74 million in the same quarter last year, which indicates a positive year over year growth rate of 7.7%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, February 13th.

On average, analysts expect that Genomic Health will report full-year sales of $89.13 million for the current year, with estimates ranging from $342.00 million to $347.80 million. For the next year, analysts anticipate that the firm will report sales of $384.08 million per share, with estimates ranging from $380.22 million to $387.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Genomic Health.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Wednesday, November 8th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.04. Genomic Health had a negative net margin of 1.30% and a negative return on equity of 1.79%.

Several research firms recently issued reports on GHDX. Canaccord Genuity reiterated a “buy” rating and issued a $42.00 target price on shares of Genomic Health in a research note on Tuesday. Zacks Investment Research upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday, October 13th. JPMorgan Chase & Co. cut shares of Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price objective for the company. in a research report on Wednesday, December 13th. ValuEngine cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. Genomic Health currently has an average rating of “Hold” and a consensus price target of $32.33.

Genomic Health (NASDAQ:GHDX) traded up $0.03 on Friday, hitting $33.48. 112,352 shares of the company traded hands, compared to its average volume of 180,133. Genomic Health has a 1 year low of $26.37 and a 1 year high of $37.50. The firm has a market cap of $1,160.00, a PE ratio of -257.54 and a beta of 0.65.

In other news, insider James J. Vaughn sold 1,379 shares of the stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Laura Leber sold 21,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $33.29, for a total transaction of $699,090.00. The disclosure for this sale can be found here. Insiders have sold 75,717 shares of company stock valued at $2,508,132 over the last 90 days. 46.20% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Aurora Investment Counsel acquired a new stake in shares of Genomic Health in the fourth quarter valued at about $1,879,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Genomic Health in the third quarter valued at about $444,000. GSA Capital Partners LLP raised its position in shares of Genomic Health by 43.7% in the third quarter. GSA Capital Partners LLP now owns 63,100 shares of the medical research company’s stock valued at $2,025,000 after buying an additional 19,200 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Genomic Health in the third quarter valued at about $138,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Genomic Health in the third quarter valued at about $350,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/19/zacks-analysts-expect-genomic-health-inc-ghdx-will-announce-quarterly-sales-of-89-13-million.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply